Increasing levels of neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) after drug discontinuation may identify previously stable MS patients at risk of new disease activity, according to Comprehensive Longitudinal Investigation of MS at the Brigham and Women’s Hospital (CLIMB) investigators (Bose et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200167; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC10574823/pdf/NXI-2023-000383.pdf ). Read More
Latest News
Exploring the lung-brain axis in MS
November 29, 2023An emerging concept in MS research is the role of the lung microbiome in promoting disease severity, with preliminary evidence showing that pulmonary micro-organisms can regulate autoimmunity in the central nervous system (reviewed in Chen et al. Int J Mol Sci 2023;24:2170). Read More
Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies
November 22, 2023Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.
11 slides
OCT – diagnosis and prognosis
November 8, 2023ECTRIMS-ACTRIMS 2023 presented new data on the use of optical coherence tomography (OCT) as a biomarker in multiple sclerosis. The following is a brief summary of recent findings. Read More